1030.9000 16.10 (1.59%)
NSE Oct 26, 2026 14:45 PM
Volume: 232.4K
 

1030.90
1.59%
Geojit BNP Paribas
The company reiterated its FY28 revenue target of $400 million, supported by a pipeline of 60+ pending low-competition U.S. product launches. Management also remains optimistic about other regulated markets, where portfolio expansion and new customer additions are expected to drive stronger growth and gradually scale revenues to levels comparable to the U.S. business....
Strides Pharma has gained 26.56% in the last 1 Year
More from Strides Pharma Science Ltd.
Recommended